PH12022551373A1 - Stabilization of retromer for the treatment of alzheimer`s disease and other neurodegenerative disorders - Google Patents
Stabilization of retromer for the treatment of alzheimer`s disease and other neurodegenerative disordersInfo
- Publication number
- PH12022551373A1 PH12022551373A1 PH1/2022/551373A PH12022551373A PH12022551373A1 PH 12022551373 A1 PH12022551373 A1 PH 12022551373A1 PH 12022551373 A PH12022551373 A PH 12022551373A PH 12022551373 A1 PH12022551373 A1 PH 12022551373A1
- Authority
- PH
- Philippines
- Prior art keywords
- disease
- alzheimer
- retromer
- ftld
- ftd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943999P | 2019-12-05 | 2019-12-05 | |
| US202063074578P | 2020-09-04 | 2020-09-04 | |
| PCT/US2020/063627 WO2021113824A1 (en) | 2019-12-05 | 2020-12-07 | Stabilization of retromer for the treatment of alzheimer's disease and other neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022551373A1 true PH12022551373A1 (en) | 2023-05-08 |
Family
ID=76222705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/551373A PH12022551373A1 (en) | 2019-12-05 | 2020-12-07 | Stabilization of retromer for the treatment of alzheimer`s disease and other neurodegenerative disorders |
Country Status (12)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003655A (es) | 2020-09-29 | 2023-06-22 | Neuexcell Therapeutics Inc | Vector neurod1. |
| US20250161243A1 (en) * | 2022-02-21 | 2025-05-22 | The Scripps Research Institute | Mef2 transcriptional activators to treat neurologic conditions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007047796A2 (en) * | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20080214482A1 (en) * | 2005-11-15 | 2008-09-04 | Scott Small | Retromer-based assays and methods for treating alzheimer's disease |
| WO2009108274A2 (en) * | 2008-02-26 | 2009-09-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
| EP2607900A1 (de) * | 2011-12-22 | 2013-06-26 | Protagen AG | Markersequenzen für Brustkrebs und deren Verwendung |
| BR112014020325A2 (pt) * | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| US20160250182A1 (en) * | 2013-01-11 | 2016-09-01 | The Trustees Of Columbia University In The City Of | Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk |
| WO2014110481A2 (en) * | 2013-01-11 | 2014-07-17 | The Trustees Of Columbia University In The City Of New York | Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson' s disease risk |
| GB201409519D0 (en) * | 2014-05-29 | 2014-07-16 | Univ Leicester | Senescent cell biomarkers |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| WO2018112446A2 (en) * | 2016-12-18 | 2018-06-21 | Selonterra, Inc. | Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease |
| EP3692158A4 (en) * | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| US20190345516A1 (en) * | 2018-03-12 | 2019-11-14 | Musc Foundation For Research Development | Methods for treating eye disease |
-
2020
- 2020-12-07 BR BR112022011073A patent/BR112022011073A2/pt unknown
- 2020-12-07 CN CN202510180683.1A patent/CN120114618A/zh active Pending
- 2020-12-07 CN CN202080093935.2A patent/CN115297891A/zh active Pending
- 2020-12-07 WO PCT/US2020/063627 patent/WO2021113824A1/en not_active Ceased
- 2020-12-07 IL IL293599A patent/IL293599A/en unknown
- 2020-12-07 AU AU2020395327A patent/AU2020395327A1/en not_active Abandoned
- 2020-12-07 MX MX2022006895A patent/MX2022006895A/es unknown
- 2020-12-07 US US17/782,357 patent/US20230021959A1/en not_active Abandoned
- 2020-12-07 JP JP2022533615A patent/JP2023505271A/ja not_active Withdrawn
- 2020-12-07 CA CA3160785A patent/CA3160785A1/en active Pending
- 2020-12-07 KR KR1020227022902A patent/KR20220152192A/ko not_active Ceased
- 2020-12-07 PH PH1/2022/551373A patent/PH12022551373A1/en unknown
- 2020-12-07 EP EP20896932.9A patent/EP4069315A4/en active Pending
-
2025
- 2025-07-28 JP JP2025125690A patent/JP2025149978A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120114618A (zh) | 2025-06-10 |
| EP4069315A1 (en) | 2022-10-12 |
| IL293599A (en) | 2022-08-01 |
| EP4069315A4 (en) | 2024-03-20 |
| KR20220152192A (ko) | 2022-11-15 |
| CN115297891A (zh) | 2022-11-04 |
| JP2023505271A (ja) | 2023-02-08 |
| CA3160785A1 (en) | 2021-06-10 |
| AU2020395327A1 (en) | 2022-07-21 |
| JP2025149978A (ja) | 2025-10-08 |
| WO2021113824A1 (en) | 2021-06-10 |
| US20230021959A1 (en) | 2023-01-26 |
| BR112022011073A2 (pt) | 2022-09-20 |
| MX2022006895A (es) | 2022-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021163681A3 (en) | Combination of retromer pharmacological chaperones and exogenous retromer for treatment of alzheimer's disease and other neurodegenerative diseases | |
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| PL4259796T3 (pl) | Środki terapeutyczne do leczenia zaburzeń neurodegeneracyjnych | |
| MX2022006895A (es) | Estabilizacion de retromero para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| TN2018000322A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| JOP20190227A1 (ar) | تركيبات وطرق لعلاج اعتلالات السينوكلين | |
| MX2017015040A (es) | Derivado de urea o sal farmacologicamente aceptable del mismo. | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| WO2019075456A3 (en) | Methods and substances for prevention and treatment of neurodegenerative diseases | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| PH12019500204A1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| ZA202100672B (en) | Further substituted triazolo quinoxaline derivatives | |
| TN2017000144A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| EA201991497A1 (ru) | Производные бензодиазепина, композиции и способы лечения когнитивного нарушения | |
| EP3810777A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | |
| EA201890090A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| MX2021000762A (es) | Derivados de triazoloquinoxalina sustituida. | |
| MX2016000724A (es) | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. | |
| CA3266556A1 (en) | PYRIDAZINONE DERIVATIVES USED AS KAT2 DEGRADING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | |
| WO2009155069A8 (en) | Compositions and methods for treating psychiatric and neurodegenerative disorders | |
| CA3263315A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT FOR PSYCHIATRIC DISORDERS | |
| CA3261797A1 (en) | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| GB202117758D0 (en) | Therapeutics for the treatment of neurodegenerative disorders | |
| WO2022204362A3 (en) | Compositions and methods for treating a neurodegenerative or developmental disorder | |
| IL299300A (en) | Materials and methods for the treatment of psychiatric disorders or their symptoms |